Related Experiment Videos
Clinically significant drug interactions with cyclosporin. An update
C Campana1, M B Regazzi, I Buggia
1Division of Cardiology, IRCCS Policlinico S. Matteo, Pavia, Italy.
Clinical Pharmacokinetics
|February 1, 1996
Summary
Cyclosporin, an immunosuppressive drug, has greatly improved organ transplant survival rates since 1983. Careful therapeutic drug monitoring is essential due to its variable pharmacokinetics and significant drug interactions.
Area of Science:
- Immunology
- Pharmacology
- Transplantation Medicine
Background:
- Cyclosporin, approved in 1983, revolutionized organ and bone marrow transplantation.
- It significantly improved graft survival and reduced morbidity across various transplant types.
- Efficacy is noted in preventing graft-versus-host disease and potential roles in autoimmune diseases and oncology.
Purpose of the Study:
- To review the impact and management of cyclosporin in transplantation.
- To highlight the importance of therapeutic drug monitoring for cyclosporin.
- To discuss significant drug-drug interactions associated with cyclosporin therapy.
Main Methods:
- Review of clinical studies and documented patient cases.
- Analysis of pharmacokinetic variability and drug interaction data.
- Emphasis on therapeutic drug monitoring strategies.
Main Results:
- Cyclosporin has dramatically enhanced 1- and 2-year graft survival rates.
- Therapeutic drug monitoring is crucial due to cyclosporin's pharmacokinetic variability.
- Numerous drug interactions can lead to adverse effects, including graft rejection and renal dysfunction.
Conclusions:
- Cyclosporin remains a cornerstone of immunosuppressive therapy in transplantation.
- Close monitoring of blood concentrations and potential drug interactions is vital for optimal patient outcomes.
- Understanding drug interactions is critical to prevent cyclosporin-related complications.